• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Faron Pharmaceuticals

0.53 EUR

+7.22 %

5,729 following

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
+7.22 %
+7.44 %
+4.36 %
-73.59 %
-72.23 %
-79.08 %
-81.84 %
-88.53 %
-84.22 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
120.09M EUR
Turnover
884.23K EUR
P/E (adj.) (26e)
-5.11
EV/EBIT (adj.) (26e)
-5.9
P/B (26e)
91.45
EV/S (26e)
28,047.04
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
0.75 EUR
Updated
11.03.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 12.03.2026

Latest extensive report

Released: 23.08.2022

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
You just can’t win with you guys. Either he speaks too little or too much. Either he’s too apathetic or too positive. Well, pleasing internet personas is likely the last thing on Juho’s mind. Do you mean to say that Big Pharma experts don’t understand what was discussed in the webcast...
9 hours ago
by OsakasOssi
31
The first recruitments for phase 2b will be in October 2026. Based on my understanding, the funds raised in the rights issue will run out before the phase 2b results, which will likely be ready for publication in Q1/28. So once again, shareholders should prepare to dig deeper into...
13 hours ago
10
That TP53 thing is interesting. Almost half of all human cancers of all types carry a TP53 mutation (just ask Google). If BEX’s capability, which was confirmed as excellent today, applied to even a fraction of those cases, the share price might even double.
8 hours ago
by Kulkuri
9
There is comprehensive coverage of research sites in the USA and Europe. Results could come surprisingly quickly if all the pieces fall into place. At the very least, it won’t be held back by the CRO (Contract Research Organization).
13 hours ago
9
I suppose it can be said more directly: the CEO apparently isn’t even trying to stay sharp in these appearances anymore. Showing up to the event looking tired and poorly prepared. Are these presentations being made for colleagues? Should the focus be more on business outlooks and...
10 hours ago
by Donkey
6
It certainly looks good. As a comment, I believe Kontro also mentioned that this 16.1 months is already very good because, according to the new metrics, 57% of these are the highest-risk patients; therefore, a direct comparison to the old AZA data cannot be made. My own understanding...
11 hours ago
by MyrtsiZzz
6
Another flagging notification from HCM; they are steadily reducing their position all the time, as could be expected. Now they have at least managed to sell about a million shares between June 4th and June 11th. Trading volume is brisk today as well, so they should gradually disappear...
11 hours ago
by Tuul1puku
5
Read more on our forum
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.8
2026

Interim report Q2'26

Regulatory press release11 hours ago

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Faron Pharmaceuticals EHA 2026
Webcast13 hours ago

Faron Pharmaceuticals EHA 2026

Faron Pharmaceuticals
Press release20 hours ago

Faron Presents Matured BEXMAB Data at EHA 2026 Confirming Durable Efficacy and Bone Marrow Reprogramming in HR-MDS

Faron Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release6/11/2026, 2:05 PM

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release6/11/2026, 2:00 PM

Faron Pharmaceuticals Ltd: Registration of Treasury Shares

Faron Pharmaceuticals
Regulatory press release6/10/2026, 4:45 PM

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release6/8/2026, 4:30 PM

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release6/5/2026, 10:50 AM

Faron Pharmaceuticals Receives Decision from Nasdaq Helsinki Disciplinary Committee

Faron Pharmaceuticals
Regulatory press release6/4/2026, 12:00 PM

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release6/3/2026, 11:00 AM

Faron Pharmaceuticals Ltd: Registration of New Shares

Faron Pharmaceuticals
Regulatory press release6/3/2026, 6:00 AM

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds

Faron Pharmaceuticals
Regulatory press release6/1/2026, 12:00 PM

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release5/28/2026, 1:00 PM

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release5/28/2026, 12:35 PM

Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company

Faron Pharmaceuticals
Regulatory press release5/28/2026, 12:30 PM

Faron Pharmaceuticals Ltd: Special Rights attached to the First and Second Tranche of Bonds

Faron Pharmaceuticals
Regulatory press release5/18/2026, 6:00 AM

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Press release5/13/2026, 6:00 AM

Faron to present new BEXMAB translational and clinical data in HR-MDS at EHA 2026

Faron Pharmaceuticals
Regulatory press release5/6/2026, 6:00 AM

Faron Pharmaceuticals Ltd: Termination of Liquidity Provision Service

Faron Pharmaceuticals
Regulatory press release5/5/2026, 7:30 AM

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release5/5/2026, 6:00 AM

Faron Pharmaceuticals Ltd: Directorate Appointment

Faron Pharmaceuticals